alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 60, Number 94 (Tuesday, May 16, 1995)]
[Notices]
[Pages 26069-26070]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-11986]



=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF STATE

[Public Notice 2204]


Advisory Committee on International Communications and 
Information Policy; Public Meeting

    The Department of State is holding the first meeting of its 
Advisory Committee on International Communications and Information 
Policy. The Committee was reestablished on August 11, 1994, in order to 
provide a formal channel for regular consultation and coordination on 
major economic, social and legal issues and problems in international 
communications and information policy, especially as these issues and 
problems involve users of information and communication services, 
providers of such services, technology research and development, 
foreign industrial and regulatory policy, the activities of 
international organizations with regard to communications and 
information, and developing country interests.
    Members of the committee have been appointed recently by Ambassador 
Vonya B. McCann, United States Coordinator for International 
Communications and Information Policy, U.S. Department of State.
    The purpose of this meeting will be to discuss issues of interest 
to the new members of the committee in order to establish a work plan 
for future meetings of the committee. Meetings will be held quarterly 
throughout the year.
    The committee will follow the procedures prescribed by the Federal 
Advisory Committee Act (FACA). Meetings will be open to the public 
unless a determination is made in accordance with the FACA section 
10(d), 5 U.S.C. 552b(c)(1) and (4) that a meeting or a portion of the 
meeting should be closed to the public.
    The first meeting will be held on Tuesday, June 6, 1995, from 10 
a.m.-12:30 p.m. in Room 1107 of the Main Building of the U.S. 
Department of State, located at 2201 ``C'' Street, NW., Washington, DC 
20520. While the meeting is open to the public, admittance to the State 
Department Building is only by means of a pre-arranged clearance list. 
In order to be placed on the pre-clearance list, please provide your 
name, title, company, social security number, and date of birth to 
Celia Arrington at (202) 647-5212 or by fax at (202) 647-5957. All 
attendees must use the ``C'' Street entrance. One of the following 
valid ID's will be required for admittance: any U.S. driver's license 
with photo, a passport, or a U.S. Government agency ID.
    For further information, contact the Executive Secretary of the 
committee, at (202) 647-5385.

     [[Page 26070]] Dated: May 3, 1995.
Timothy C. Finton,
Executive Secretary, Advisory Committee for International 
Communications and Information Policy.
[FR Doc. 95-11986 Filed 5-15-95; 8:45 am]
BILLING CODE 4710-45-M
Haz lo correcto.

“No lavé, enjuagué ni 

desinfecté el 

fregadero”.

“Lavé, enjuagué y 

desinfecté el fregadero”.

Protege a todos. Siempre lave, enjuague y desinfecte los equipos entre usos.
### IN THE UNITED STATES COURT OF APPEALS FOR THE FIFTH CIRCUIT

No. 17

- 30202

MERCATO ELISIO, L.L.C.,

Plaintiff

- Appellant

v. JOHN J. DEVENEY, III, improperly named John Deveney; DEVENEY COMMUNICATION CONSULTING, L.L.C.; CHRIS COSTELLO, individually and as employee of Deveney Communication Consulting, L.L.C.,

Defendants

- Appellees

Appeal from the United States District Co urt for the Eastern District of Louisiana USDC No. 2:15

- CV

- 563

Before HIGGINBOTHAM, JONES, and GRAVES, Circuit Judges

. PER CURIAM: * The court has carefully considered this appeal in light of the briefs, oral argument and pe rtinent portions of the record. Having done so, we conclude that the claims appellant asserts against these appellees accrued, under either federal or state law, as early as August 2012 or April 2013, triggering the comm encement of the one

- year Louisiana prescription

* Pursuant to 5 TH C IR . R. 47.5, the court has determined that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5 TH C IR . R. 47.5.4. United States Court of Appeals Fifth Circuit 

### FILED December 13, 2017 Lyle W. Cayce Clerk Case: 17-30202 Document: 00514271082 Page: 1 Date Filed: 12/13/2017No. 17

- 30202

2 period. Piotrowski v. City of Houston , 51 F.3d 512 , 516 (5th Cir. 1995); Elzy v. Roberson , 868 F.2d 7 93, 794 (5th Cir. 1989); Ziegler v. Hous. Auth. Of New Orleans , 118 So.3d 442, 452 (La. App. 4 Cir. 2013). Appellant’s suit, filed on February 20 , 2015, is well outside this period. Further, there was no basis for equitable tolling of prescription because appellees’ actions did

not amount to the level of active concealment necessary to implicate the jurispru dential exception, contra non valentem

. F.D.I.C. v. Barton , 96 F.3d 128, 135 (5th Cir. 1996) (t o suspend the running of the prescriptive period there must be evidence of “fraud, deceit, misrepresentation or concealment by the defendants that led to the plaintiff’s failure to file the cl aim within the statutory period ”)

. These conclusions were we ll stated in the district
court’ s opinion, with which we essentially agree. JUDGMENT
AFFIRMED

. Case: 17-30202 Document: 00514271082 Page: 2 Date Filed: 12/13/2017
EXHIBIT 4

Manually 

Filed

Case 3:16-cv-07222-SK Document 78-4 Filed 12/31/18 Page 1 of 1
Exhibit 32.1



CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002





In connection with the Quarterly Report of Thunder Mountain Gold, Inc., (the "Company") on Form 10-Q for the period ending March 31, 2010, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, E. James Collord, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:



1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and



2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Thunder Mountain Gold, Inc.







/s/ E. James Collord

DATE:  May 20, 2010

E. James Collord, President and Chief Executive Officer





A signed original of this written statement required by Section 906 has been provided to Thunder Mountain Gold, Inc. and will be retained by Thunder Mountain Gold, Inc. to be furnished to the Securities and Exchange Commission or its staff upon request.
Exhibit 31.2
 CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
  1.
    
    I have reviewed this quarterly report on Form 10-Q of Axcess International, Inc.;
 2.
    
    Based on my knowledge, this quarterly report does not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this quarterly report;
 3.
    
    Based on my knowledge, the financial statements, and other financial information
included in this quarterly report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the
periods presented in this quarterly report;
 4.
    
    The registrants other certifying officers and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal controls over financial reporting (as defined Exchange Act
Rules 13-15(f) and 15d-(f)) for the registrant and we have:
 a)
    
    designed such disclosure controls and procedures to ensure that
material information relating to the registrant, including its consolidating
subsidiaries, is made known to us by others within those entities, particularly
during the period in which this quarterly report was prepared;
 b)
    
    evaluated the effectiveness of the registrants disclosure controls and
procedures as of the end of the period covered by this quarterly report (the
Evaluation Date); and
 c)
    
    presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on the required
evaluation as of the Evaluation Date;
 5.
    
    The registrants other certifying officers and I have disclosed, based on our most
recent evaluation, to the registrants auditors and the audit committee of registrants
board of directors (or persons performing the equivalent function):
 a)
    
    all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrants ability to record, process,
summarize and report financial data and have identified for the registrants
auditors any material weaknesses in internal controls; and
 b)
    
    any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrants internal controls; and
 6.
    
    The registrants other certifying officers and I have indicated in this quarterly
report whether or not there were significant changes in internal controls or in other
factors that could significantly affect internal controls subsequent to the date of our
most recent evaluation, including any corrective actions with regard to significant
deficiencies and material weaknesses.
  /s/ ALLAN L. FRANKAllan L. Frank, Vice President, Chief Financial Officer and Secretary(Principal Accounting and Financial Officer)
Angela TAGLIAFERRI and Betsy Stephens, petitioners, v. WINTER PARK HOUSING AUTHORITY, et al.

No. 12-7976.

Supreme Court of the United States

April 29, 2013.

Petition for rehearing denied.
EX-10.1






Exhibit 10.1




G-III Apparel Group, Ltd.

512 Seventh Avenue

New York, New York 10018




January 28, 2009




Morris Goldfarb

21 Fairway Drive

Mamaroneck, New York 10543





			
	           Re:	 	Employment Agreement





Dear Morris:




     Reference is made to the Employment Agreement, dated February 1, 1994, as amended October 1,
1999 (as so amended, the “Employment Agreement”), between G-III Apparel Group, Ltd. and you.



     This letter agreement, when executed by you, shall constitute our agreement that, for the six
month period commencing February 1, 2009, your salary pursuant to Section 3(a) of the Employment
Agreement shall be paid at the rate of $800,000 per year.



     This Letter Agreement may be executed by the parties hereto in one or more counterparts, each
of which shall be deemed an original and all of which when taken together shall constitute one and
the same agreement. Any signature delivered by a party by facsimile transmission, or in “PDF”
format circulated by electronic means, shall be deemed to be an original signature hereto.



     If the foregoing accurately sets forth our agreement, please execute this letter and return it
to the undersigned.



	 	 	 	 	 	 	 
	 	 	Very truly yours,	 	 
	 
	 	 	 	 	 	 
	 	 	G-III APPAREL GROUP, LTD.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Wayne Miller
 

	 	 
	 

	 	 	 	Name: Wayne Miller	 	 
	 

	 	 	 	Title: Chief Operating Officer	 	 
	 
	 	 	 	 	 	 
	Accepted and agreed to:
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	/s/ Morris Goldfarb
 

MORRIS GOLDFARB
Lance D. HOLLAND, petitioner, v. Harold W. CLARKE, Director, Virginia Department of Corrections.

No. 12-8603.

Supreme Court of the United States

April 15, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Fourth Circuit denied.
Bernard JEMISON, petitioner, v. Shirley NUNN.

No. 12-8592.

Supreme Court of the United States

April 15, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Eleventh Circuit denied.
[Federal Register Volume 60, Number 95 (Wednesday, May 17, 1995)]
[Notices]
[Pages 26424-26425]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-12056]



-----------------------------------------------------------------------

DEPARTMENT OF ENERGY
Federal Energy Regulatory Commission
[Docket No. RP92-237-016]


Alabama-Tennessee Natural Gas Company; Notice of Filing of a 
Corrected Refund Report

May 11, 1995.
    Take notice that on April 4, 1995, Alabama-Tennessee Natural Gas 
Company (Alabama-Tennessee), tendered for filing a corrected refund 
report in compliance with ordering paragraph (F) of the Commission's 
March 20, 1995 order in Docket No. RP92-237-013, et al.
    Consistent with ordering paragraph (E) of the March 20 order 
Alabama-Tennessee states that it sent letters on March 27, 1995, 
offering each of its customers that had an effective Operational 
Balancing Agreement (OBA) the option of receiving refunds for fuel 
retainage either in-kind, or as a credit to the customer's OBA account. 
Alabama-Tennessee further states that it has calculated interest at the 
rates [[Page 26425]] mandated by Commisison regulations, and has 
applied the resulting percentage figures to the retained gas volumes 
for each customer, thereby paying the interesting as volumes.
    All parties that have already filed comments or protests regarding 
the subject corrected refund report need not file in response to this 
notice.
    Any person desiring to protest said filing should file a protest 
with the Federal Energy Regulatory Commission, 825 North Capitol 
Street, N.E., Washington, DC 20426, in accordance with 385.211 of the 
Commission's Rules and Regulations. All such protests should be filed 
on or before May 18, 1995. Protests will be considered by the 
Commission in determining the appropriate action to be taken but will 
not serve to make protestants parties to the proceeding. Copies of this 
filing are on file with the Commission and are available for public 
inspection.
Lois D. Cashell,
Secretary.
[FR Doc. 95-12056 Filed 5-16-95; 8:45 am]
BILLING CODE 6717-01-M
EXHIBIT B

case 4:13-cv-00027-JD-JEM document 18-2 filed 08/16/13 page 1 of 1
AMERICAN FUEL & PETROCHEMICAL MANUFACTURERS, et al., petitioners, v. ENVIRONMENTAL PROTECTION AGENCY, et al.

No. 12-1229.

Supreme Court of the United States

June 24, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the District of Columbia Circuit denied.
IN THE UNITED STATES DISTRICT COURT 

NORTHERN DISTRICT OF INDIANA 

SOUTH BEND DIVISION 

CAROLYN MALONEY, c/o ) 

Denny Maloney, ) 

 ) 

 Plaintiff, ) 

 ) 

v. ) Cause No. 3:12-CV-842-PPS-CAN 

 ) 

NEW ENGLAND COMPOUNDING ) 

PHARMACY, INC. a/k/a NEW ) 

ENGLAND COMPOUNDING CENTER; ) 

AMERIDOSE, LLC; ALAUNUS ) 

PHARMACEUTICAL, LLC; BARRY ) 

CADDEN; LISA CADDEN; ) 

and GREGORY CONIGLIARO, ) 

 ) 

 Defendants. ) 

NOTICE OF STAY BY REASON OF BANKRUPTCY

 The defendant, New England Compounding Pharmacy, Inc. d/b/a New England 

Compounding Center (“NECC”), hereby notifies the Court that NECC filed a voluntary petition 

under Chapter 11 of Title 11 of the United States Bankruptcy Code in the United States 

Bankruptcy Court for the District of Massachusetts (Eastern Division) No. 12-19882-HJB. 

Pursuant to 11 U.S.C. § 362(a), all actions against NECC are stayed. 

LEWIS WAGNER LLP 

By: /s/ Dina M. Cox 

DINA M. COX, #18590-49 

KAMEELAH SHAHEED-DIALLO, #28058-49 

ROBERT M. BAKER IV, #25471-49 

 Attorneys for Defendant, New England 

Compounding Pharmacy, Inc. 

 

case 3:12-cv-00842-PPS-CAN document 8 filed 12/27/12 page 1 of 2
2 

CERTIFICATE OF SERVICE

 This is to certify that a copy of the foregoing has been filed with the Clerk of the Court 

on December 27, 2012 using the CM/ECF system which sent notification of this filing to the 

following: 

Douglas A. Mulvaney 

STUTSMAN & MULVANEY 

1300 Cassopolis Street 

P.O. Box 1337 

Elkhart, Indiana 46515 

/s/ Dina M. Cox

 DINA M. COX 

LEWIS WAGNER, LLP 

501 Indiana Avenue, Suite 200 

Indianapolis, IN 46202 

Phone: (317) 237-0500 

FAX: (317) 630-2790 

dcox@lewiswagner.com Q:\NECC\14 - Maloney\Federal Court Action\Notice of Stay_Bankruptcy.docx

case 3:12-cv-00842-PPS-CAN document 8 filed 12/27/12 page 2 of 2
ALABAMA LEGISLATIVE BLACK CAUCUS, et al., appellants, v. ALABAMA, et al.

No. 13-395.

Supreme Court of the United States

Dec. 2, 2013.

On appeal from the United States District Court for the Middle District of Alabama. Appeal dismissed for want of jurisdiction.
Milburn L. EDWARDS, petitioner, v. Arvil CHAPMAN, Warden.

No. 12-9299.

Supreme Court of the United States

April 15, 2013.

Petition for writ of certiorari to the Court of Criminal Appeals of Tennessee, Middle Division, denied.
피내 JYNNEOS 원숭이두창 백신 요약 정보

• 원숭이두창에 감염될 위험이 있는 모든 사람들이 백신을 사용할 수 있도록 하는 것이 USG의 최우선 과제입니다.

• JYNNEOS는 피하 또는 피내 경로로 안전하게 투여할 수 있습니다.

• 면역 반응은 두 가지 다른 투여 경로를 사용하여도 유사합니다.

• 피내 투여는 현재 커뮤니티의 가장 광범위한 보호를 가능하게 해줍니다.

빠르게 진화하는 원숭이두창의 발병으로 인해 위험에 처한 사람들의 면역학적 보호를 위해 사용 가능한 모든 백신 옵션을 모색해야

했습니다. JYNNEOS 원숭이두창 백신의 현재 사용 가능한 용량의 수는 피하(SC) 투여로 4주 간격으로 제공되는 승인된 2회분 요법으로

혜택을 받을 수 있는 사람들에게 완전히 백신을 접종하기에 부적합한 것으로 판단되었습니다. 원숭이두창에 대한 다른 백신의 사용은

부작용으로 인해 현재로서는 권장되지 않는 것으로 판단되었습니다. 2차 JYNNEOS 백신 접종을 3~6개월 연기하는 방안도 고려했습니다. 

그러나 사용 가능한 증거를 주의 깊게 검토하고 이 전략에 정확하게 적용할 수 있는 데이터가 없음을 인정한 후, 이 옵션은 투여 기간

사이에 보호가 충분히 되지 않을 수 있고 (실제로는 그렇지 않지만) 개인에게 원숭이두창으로부터 보호된다는 잘못된 보안 인식을 제공할

수 있기 때문에 권장하지 않는 것으로 결정되었습니다.

공급과 수요의 불일치를 해결하기 위해, 피내(ID) 경로를 통한 백신 투여가 재고를 확장하기 위한 전략으로 간주되었습니다. 일부 백신은

피부 층 사이에 소량으로 투여할 수 있으며 피부 아래의 조직에 투여될 때와 매우 유사한 면역 반응을 일으킬 수 있습니다.

1 JYNNEOS, 

Modified Vaccinia Ankara (MVA)에서 사용 된 바이러스는 원래 수천 명의 어린이와 성인에게 ID 경로로 1970년대에 투여되었으며, 그

이후로 다른 백신과 함께 임상 시험에서 ID로 투여되었습니다.

2 또한, JYNNEOS는 국립 알레르기 및 전염병 연구소(NIAID)가 후원하는

연구에서 SC와 비교하여 ID로 투여된 2회분 용량 시리즈로 평가되었습니다. 백신을 ID 경로로 투여 받은 개인은 피부층 사이의

주사하도록 조정된 투여량을 받았습니다. 평가된 ID 경로를 통한 투여 용량은 SC 용량(0.5mL)의 1/5(0.1mL)이었습니다.

NIAID 연구의 결과는 ID 투여가 여러 항체 반응 테스트를 기반으로 SC 투여에 대해 매우 유사한 면역 반응을 생성하고 SC 및 ID 경로가

동일하지는 않지만 유사한 세포 면역 반응을 생성한다는 것을 입증했습니다.

3

ID 투여는 주사 부위의 발적, 단단함, 가려움증 및 부기가 더

많았지만 통증은 덜했으며 이러한 부작용은 관리할 수 있었습니다. 흥미롭게도 NIAID 연구에서 JYNNEOS의 ID 투여로 보고된 부작용

프로필은 1970년대에 MVA가 ID 경로로 투여되었을 때 설명된 부작용 프로필을 매우 밀접하게 반영했습니다.

2

FDA는 이용 가능한 증거의 전체를 신중히 검토하고 사용 가능한 모든 옵션을 고려하여 감염 위험이 높은 것으로 판단된 18세 이상의

개인들에게 ID 경로로 JYNNEOS를 투여하는 것 뿐만 아니라 감염 위험이 높은 것으로 판단된 18세 미만의 개인들이 백신을 SC 경로로

투여 받을 수 있도록 허용하기 위해, 긴급 사용 승인(EUA) 기준이 충족되었다고 판단했습니다. 

4

안정성 정보에 기초하여, 승인된 백신은 이제 +2°C ~ +8°C(+36°F ~ +46°F)에서 해동된 후 최대 8주 동안 보관할 수 있습니다. 바이알에

구멍을 뚫고 용량을 빼낸 후 전체를 사용하지 않으면 +2°C ~ +8°C(+36°F ~ +46°F)에 보관하고 최초로 구멍을 뚫은 후 8시간 이내에

폐기해야 합니다. 각 바이알에서 얻을 수 있는 용량의 수를 최대화하기 위해 최소 잔여형 주사기와 바늘(27 게이지)을 사용해야 합니다.

5

1 Hickling JK 등. Bull World Health Organ 2011; 89:221-226.

2 Stickl HA, Preventive Medicine(예방 의학), 1974; 3:97-101; Stickl H 등. Dtsch med Wschr 1974; 99:2386-2392. (참고: 요청 시,

이 기사의 영어 번역본은 FDA에서 이메일로ocod@fda.hhs.gov) 받을 수 있습니다.

3 Frey SE 등. 백신 2015; 33:5225-5234; Frey SE 등. J Infect Dis; 2021; 224:1372-1382.

4 검토 보고서 및 팩트 시트를 포함한 EUA 자료는 온라인으로 제공됩니다.

5 투여에 관한 추가 정보 및 자료는 2022년 8월 10일의 DHCP 서신을 참조하십시오.
case 3:13-cv-00052-PPS-CAN   document 38   filed 07/23/13   page 1 of 19

case 3:13-cv-00052-PPS-CAN   document 38   filed 07/23/13   page 2 of 19

case 3:13-cv-00052-PPS-CAN   document 38   filed 07/23/13   page 3 of 19

case 3:13-cv-00052-PPS-CAN   document 38   filed 07/23/13   page 4 of 19

case 3:13-cv-00052-PPS-CAN   document 38   filed 07/23/13   page 5 of 19

case 3:13-cv-00052-PPS-CAN   document 38   filed 07/23/13   page 6 of 19

case 3:13-cv-00052-PPS-CAN   document 38   filed 07/23/13   page 7 of 19

case 3:13-cv-00052-PPS-CAN   document 38   filed 07/23/13   page 8 of 19

case 3:13-cv-00052-PPS-CAN   document 38   filed 07/23/13   page 9 of 19

case 3:13-cv-00052-PPS-CAN   document 38   filed 07/23/13   page 10 of 19

case 3:13-cv-00052-PPS-CAN   document 38   filed 07/23/13   page 11 of 19

case 3:13-cv-00052-PPS-CAN   document 38   filed 07/23/13   page 12 of 19

case 3:13-cv-00052-PPS-CAN   document 38   filed 07/23/13   page 13 of 19

case 3:13-cv-00052-PPS-CAN   document 38   filed 07/23/13   page 14 of 19

case 3:13-cv-00052-PPS-CAN   document 38   filed 07/23/13   page 15 of 19

case 3:13-cv-00052-PPS-CAN   document 38   filed 07/23/13   page 16 of 19

case 3:13-cv-00052-PPS-CAN   document 38   filed 07/23/13   page 17 of 19

case 3:13-cv-00052-PPS-CAN   document 38   filed 07/23/13   page 18 of 19

case 3:13-cv-00052-PPS-CAN   document 38   filed 07/23/13   page 19 of 19
Diverse Women in Clinical Trials Initiative
 

Organizational Opportunities Form
 

We have made progress in women’s participation in clinical trials. To continue this momentum, 

the U.S. Food and Drug Administration Office of Women’s Health (FDA OWH) is partnering with 

the National Institutes of Health Office of Research on Women’s Health (NIH ORWH) to 

promote clinical trial participation by diverse women of all ages and ethnicities, as well as those 

with various chronic health conditions and disabilities. 

How you can help... 

Link to the website: www.fda.gov/womeninclinicaltrials 

Send out an article or announcement via your newsletter, magazine or social media 

channels (Pre-drafted messages are available.) 

Incorporate our free Campaign materials into your existing activities and events 

Host a webinar or outreach event 

Use the NIH Outreach Toolkit to encourage recruitment of women in clinical research 

What you do to support the Campaign depends upon the needs and resources of your 

organization. 

Contact Information 

Organization:
 

Contact Person:
 

Title:
 

Address:
 

Email Address:
 

Telephone:
 

Website:
 
 

 

 

 

 

Thank you for your interest in supporting the FDA Office of Women’s Health Diverse Women in 

Clinical Trials Initiative. Please have your organization’s authorizing official sign, date and fax 

this form to (301) 847-8601. Your FDA OWH contact is: . 

Name (print): 

Signature: 

Date: 

Agree to be listed publicly as a supporter of the Diverse Women in Clinical Trials 

Initiative 

This form in no way indicates a formal partnership between the FDA or its agents and the above 

signed individual or organization. Your organization is not obligated to conduct any of the 

activities indicated on this form. Your contact information will not be shared with other 

agencies without your written consent. 

The FDA does not endorse or sponsor the above organization, its products, or services. 

January 2020